Oklo Inc. officer Vivek Narayanadas submitted a Form 144 notice of proposed sale on November 13, 2026, indicating an intent to sell 936 Class A shares with an aggregate market value of $22,055.25 through Fidelity Brokerage Services LLC on the NYSE.
Tonix Pharmaceuticals Holding Corp. filed a complaint for patent infringement against Dr. Reddy's Laboratories in the U.S. District Court for the District of New Jersey on November 13, 2026, following Dr. Reddy's submission of an ANDA for a generic version of TONMYA.
aTyr Pharma, Inc. filed a Form 8-K on November 13, 2026, disclosing that Nasdaq notified the company it had regained compliance with the minimum closing bid price requirement after its common stock closed at $1.00 per share or greater for 10 consecutive business days.
Advasa Holdings, Inc. filed a Form 8-K on November 13, 2026, disclosing the appointment of Andre Thompson as an Independent Non-Executive Director, effective November 10, 2026.
Grupo Cibest S.A. filed a Form 6-K with the SEC on November 13, 2026, furnishing its quarterly report for the fiscal quarter ended September 30, 2026, prepared in accordance with International Financial Reporting Standards.
Moderna, Inc. filed a Form 8-K on November 13, 2026, disclosing a Transitional Services and Retirement Agreement with Chief Legal Officer Shannon Thyme Klinger, outlining the terms of her departure from the company.
Santander Holdings USA, Inc. filed a quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission covering the quarterly period ended September 30, 2026, disclosing condensed consolidated financial statements, management discussion, and risk factor updates.
DoorDash, Inc. filed a Form 425 on November 13, 2026, relating to its proposed acquisition of Maplebear Inc. (Instacart), featuring statements from regional and independent grocers and state retail associations in support of the combination.
ICZOOM Group Inc. filed a Form 6-K on November 13, 2026, disclosing the resignation of Hantao Cui from her roles as director and Chief Strategy Officer, effective November 11, 2026.
Director and 10% owner John Simard filed a Form 4 with the SEC on November 13, 2026, reporting the open-market purchase of 70,000 shares of XBiotech Inc. common stock on November 3, 2026.